A single-arm, open, multicenter and exploratory clinical study of fluzopari combined with apatinib in pts with platinum-sensitive relapsed ovarian cancer first-line treated with a PARP inhibitor

被引：0
|
作者：
Wang, J. [1 ]
Shen, Y. [1 ]
Chen, J. [2 ]
Chen, X. [3 ]
Guan, Q. [4 ]
Liu, Q. [5 ]
Xu, J. [6 ]
Xu, Y. [7 ]
Zhang, B. [8 ]
Zhang, H. [9 ]
Zhu, Y. [10 ]
Zhang, Y. [11 ]
机构：
[1] Jiangsu Canc Hosp, Gynecol, Nanjing, Peoples R China
[2] Second Peoples Hosp Changzhou, Gynecol, Changzhou, Jiangsu, Peoples R China
[3] First Peoples Hosp Yancheng, Gynecol, Yancheng, Peoples R China
[4] Jiangsu Hosp Tradit Chinese Med, Gynecol, Nanjing, Peoples R China
[5] Nanjing Med Univ, Jiangning Hosp, Gynecol, Nanjing, Peoples R China
[6] Subei Peoples Hosp Jiangsu Prov, Gynecol, Yangzhou, Jiangsu, Peoples R China
[7] First Peoples Hosp Changzhou, Gynecol, Changzhou, Jiangsu, Peoples R China
[8] Fourth Peoples Hosp Xuzhou, Xuzhou Cent Hosp, Gynecol, Xuzhou, Jiangsu, Peoples R China
[9] Nanjing Med Univ, Nanjing Matern & Child Hlth Care Hosp, Gynecol, Nanjing, Peoples R China
[10] Xuzhou Third Peoples Hosp, Xuzhou Canc Hosp, Gynecol, Xuzhou, Jiangsu, Peoples R China
[11] First Peoples Hosp Lianyungang, Gynecol, Lianyungang, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.238
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
202P
引用
收藏
页码：S1513 / S1513
页数：1
相关论文
共 50 条
  • [21] Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
    Yuan, Li
    Jia, Guo-Dong
    Lv, Xiao-Fei
    Xie, Si-Yi
    Guo, Shan-Shan
    Lin, Da-Feng
    Liu, Li-Ting
    Luo, Dong-Hua
    Li, Yi-Fu
    Deng, Shen-Wen
    Guo, Ling
    Zeng, Mu-Sheng
    Cai, Xiu-Yu
    Liu, Sai-Lan
    Sun, Xue-Song
    Li, Xiao-Yun
    Li, Su-Chen
    Chen, Qiu-Yan
    Tang, Lin-Quan
    Mai, Hai-Qiang
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [22] Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study
    Tashiro, Ryota
    Kawazoe, Hitoshi
    Mamishin, Kanako
    Seto, Keisuke
    Udagawa, Ryoko
    Saito, Yoshimasa
    Hashimoto, Hironobu
    Shimoi, Tatsunori
    Yonemori, Kan
    Yonemura, Masahito
    Terakado, Hiroyuki
    Nishimura, Takahiro
    Kawasaki, Toshikatsu
    Furukawa, Tetsuya
    Nakamura, Tomonori
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [23] Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study
    Ryota Tashiro
    Hitoshi Kawazoe
    Kanako Mamishin
    Keisuke Seto
    Ryoko Udagawa
    Yoshimasa Saito
    Hironobu Hashimoto
    Tatsunori Shimoi
    Kan Yonemori
    Masahito Yonemura
    Hiroyuki Terakado
    Takahiro Nishimura
    Toshikatsu Kawasaki
    Tetsuya Furukawa
    Tomonori Nakamura
    Scientific Reports, 13
  • [24] Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study
    Lan, Chun-Yan
    Wang, Yin
    Xiong, Ying
    Li, Jun-Dong
    Shen, Jing-Xian
    Li, Yan-Fang
    Zheng, Min
    Zhang, Yan-Na
    Feng, Yan-Ling
    Liu, Qing
    Huang, Hui-Qiang
    Huang, Xin
    LANCET ONCOLOGY, 2018, 19 (09): : 1239 - 1246
  • [25] Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ ENGOT-ov38): a phase IIIb trial
    Pujade-Lauraine, E.
    Selle, F.
    Scambia, G.
    Asselain, B.
    Marme, F.
    Lindemann, K.
    Colombo, N.
    Madryl, R.
    Glasspool, R.
    Vergote, I.
    Korach, J.
    Lheureux, S.
    Dubot, C.
    Oaknin, A.
    Zamagni, C.
    Heitz, F.
    Gladieff, L.
    Rubio-Perez, M. J.
    Scollo, P.
    Blakeley, C.
    Shaw, B.
    Ray-Coquard, I
    Redondo, A.
    ANNALS OF ONCOLOGY, 2023, 34 (12) : 1152 - 1164
  • [26] A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
    Lee, Jung-Yun
    Park, Junsik
    Lee, Jae Kwan
    Jeong, Dae Hoon
    Kim, Se Ik
    Choi, Min Chul
    Kim, Byoung-Gie
    Lim, Myong Cheol
    Park, Jeong-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Anlotinib plus chemotherapy as first-line treatment for advanced ovarian cancer: a prospective, single-arm, single-center, phase II clinical study
    Liu, Dechun
    Yan, Tao
    Zhang, Qian
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S89 - S90
  • [28] Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study
    Li, Ling
    Kong, Fei
    Zhang, Lei
    Li, Xin
    Fu, Xiaorui
    Wang, Xinhua
    Wu, Jingjing
    Zhang, Fangwen
    Ren, Liangliang
    Zhang, Mingzhi
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1847 - 1853
  • [29] Brain radiotherapy combined with camrelizumab and platinum-based chemotherapy as first-line treatment for advanced NSCLC with brain metastases: A multicenter, open-label, single-arm, phase II study
    Fan, Y.
    Xu, Y.
    Huang, Z.
    Xu, Y.
    Sheng, L.
    Li, H.
    Lu, H.
    Chen, K.
    Yu, S.
    Gong, L.
    Han, N.
    Xu, X.
    Qin, J.
    Xie, F.
    Hong, W.
    Huang, D.
    Chen, J.
    ANNALS OF ONCOLOGY, 2023, 34
  • [30] Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study
    Ling Li
    Fei Kong
    Lei Zhang
    Xin Li
    Xiaorui Fu
    Xinhua Wang
    Jingjing Wu
    Fangwen Zhang
    Liangliang Ren
    Mingzhi Zhang
    Investigational New Drugs, 2020, 38 : 1847 - 1853
12345